Do you need a Washington, DC Byetta attorney? Contact one of our Washington, DC Byetta attorneys now.
Home : Unsafe Drugs : Byetta : MSN Newsfeeds
Byetta - MSN Newsfeeds
- Reuters UK - Eli Lilly and Co.'s injectable drug Byetta, also known as exenatide, is a synthetic copy of a hormone that occurs naturally. Amylin Pharmaceuticals Inc. makes the drug with Lilly. Merck & Co Inc.'s pill, Januvia, or sitagliptin, props up ...
- United Press International - The two drugs, exenatide -- an injectable agent sold as Byetta -- and sitagliptin -- the oral drug Januvia -- utilize the incretin molecular pathway, slowing the speed at which the stomach empties, making people feel fuller and helping them from ...
- CBS News - Unlike other diabetes drugs, Byetta, Januvia, Galvus, and liraglutide don't make people gain weight. (WebMD) The newest class of type 2 diabetes drugs — Byetta, Januvia, and the still-unapproved Galvus and liraglutide — have "modest" effects with ...
- USA Today - Incretins regulate the release of insulin in response to fluctuations in blood sugar. One drug class, which includes Byetta, mimics the effect of incretins; the other class, which includes Januvia, blocks an enzyme that inactivates them. When sugar ...
- Palm Beach Post - New York-based Pfizer sells Exubera, an inhaled insulin drug, while San Diego-based Amylin Pharmaceuticals and Eli Lilly and Co. in Indianapolis are offering Byetta. Whitehouse Station, N.J.-based Merck & Co. has Januvia on the market. The latter two ...
- San Diego Business Journal - The patent for diabetes drug Byetta, made by San Diego’s Amylin Pharmaceuticals Inc., expires in 2013, according to a Citigroup Investment Research report. The Food and Drug Administration-approved diabetes drug brought in $450 million in 2006 ...
- Yahoo Finance - - BYETTA offers the added benefits of progressive weight loss and lower risk of hypoglycemia - CHICAGO, June 24 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN - News ) and Eli Lilly and Company (NYSE: LLY - News ) today ...
- Street.Com - The drug "was well-tolerated in terms of gastrointestinal side effects, particularly nausea, which could be a point of differentiation versus Byetta if approved." Byetta is made by Eli Lilly ( LLY - Cramer's Take - Stockpickr ) and Amylin Pharmaceuticals ...
- New York Times - Alternatives to Avandia include Byetta, which is marketed by Amylin Pharmaceuticals and Eli Lilly . It and others could benefit if doctors started encouraging patients to drop Avandia. So far, though, many doctors seem to be playing wait and see. ...
- MediaPost - Competitors such as Byetta--which is marketed by Amylin Pharmaceuticals and Eli Lilly--could benefit if doctors started encouraging patients to drop Avandia. But some ad industry executives say that because Glaxo has helped raise diabetes awareness ...
- MSN MoneyCentral - Its competitors include Merck's (MRK, 51.44) Januvia, Amylin Pharmaceuticals' (AMLN, 42.15) Byetta, and Takeda's (4502 JP) Actos. -- Kimberly DuBord, Briefing.com Briefing.com is the leading Internet provider of live market analysis for U.S. Stock, U.S ...
- Times Online - Rival medicines to treat type-II diabetes, including Januvia, by Merck, and Byetta, of Eli Lilly, are expected to benefit from any decline in Avandia sales. — Also known as Rosiglitazone, Avandia is an antidiabetic drug for type-II diabetes, the ...
- Washington Post - Injectable medications including Symlin and Byetta. · Insulin is often used as a last resort after pills have failed to control Type 2 diabetes. Some diabetics combine insulin with pills to treat their conditions. Has Avandia been withdrawn from the ...
- WHAS 11 - GlaxoSmithKline's loss could become Eli Lilly and Co.'s gain in the competitive market for diabetes drugs. Lilly might see a sales bump for its diabetes drug Byetta thanks to an analysis published by the New England Journal of Medicine that ties an ...
- Wall Street Journal - Among newer drugs for the disease are Merck & Co. 's pill Januvia, which is in a new class called DPP-4 inhibitors, and Eli Lilly & Co. and Amylin Pharmaceuticals Inc.'s Byetta, which is injected. The oldest drug for diabetes is insulin, which is ...
- FOX News - Eli Lilly & Co.'s Byetta is an injectable medication in a class of drugs called incretin mimetics. They are so named because they mimic the effects of naturally occurring hormones in the intestines and can help the body make more of its own insulin ...
- CNN Money - The newest drugs in this market include Merck's (up $0.07 to $52.76, Charts , Fortune 500 ) Januvia, as well as Byetta from Eli Lilly & Co (down $0.13 to $58.98, Charts , Fortune 500 ). of Indianapolis, and Amylin Pharmaceuticals (up $0.04 to $42.61, Charts ...
- Forbes - Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the company's expertise in ...
- Motley Fool - That all changed with the approvals of the company's first-in-class diabetes drugs Symlin and Byetta in 2005. These drugs propelled the company's top line over the $500 million mark in 2006. The company's stock is also up from $9.60 in May 2002 to ...
- MSN MoneyCentral - Two drugs that have recently been approved are Merck's MRK Jenuvia, which is a daily pill, and Amylin's AMLN Byetta, which is a daily injection, actually twice a day. Xoma's drug is such a high binder that it has the potential to be either a once ...
Do you need a Washington, DC Byetta attorney? Contact one of our Washington, DC Byetta attorneys now.
Pages: 1 2 3 4 5 6 ... Next
